PE20030643A1 - Procedimientos para la preparacion de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal - Google Patents

Procedimientos para la preparacion de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal

Info

Publication number
PE20030643A1
PE20030643A1 PE2002001129A PE2002001129A PE20030643A1 PE 20030643 A1 PE20030643 A1 PE 20030643A1 PE 2002001129 A PE2002001129 A PE 2002001129A PE 2002001129 A PE2002001129 A PE 2002001129A PE 20030643 A1 PE20030643 A1 PE 20030643A1
Authority
PE
Peru
Prior art keywords
alkyl
methyl
treatment
compounds
iloxi
Prior art date
Application number
PE2002001129A
Other languages
English (en)
Inventor
Ripin David Harold Brown
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20030643A1 publication Critical patent/PE20030643A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN PROCEDIMIENTO PARA PREPARAR COMPUESTOS BICICLICOS SUSTITUIDOS DE FORMULA I DONDE, m ES 0-3, p ES 0-4, R1 Y R2 SON H, ALQUILO, R3 ES C(R1R)t-HETEROCICLO OPCIONALMENTE CONDENSADO A UN BENCENO, CICLOALQUILO; t ES 0-5; R4 ES C@C(R16R17)tR9; C=C(R16R17)tR9, C@C(R16R17)kR13; C=C(R16R17)kR13; R5 ES HALO, HIDROXI, NR1R2, ALQUILO, TRIFLUOROMETILO, ALCOXI, TRIFLUOROMETOXI, NR6COR1, CONR6R7, ENTRE OTROS; R6, R7 SON H, ALQUILO, (CR1R2)tARILO, (CR1R2)tHETEROCICLICO. SON COMPUESTOS PREFERIDOS (+/-)-[3-METIL-4-(PIRIDIN-3-ILOXI)-FENIL]-(6-PIPERIDIN-3-ILETINIL-QUINAZOLIN-4-IL)-AMINA; 2-METOXI-N-(3-{4-[3-METIL-4-(PIRIDIN-3-ILOXI)-FENILAMINO]-QUINAZOLIN-6-IL}-PROP-2-INIL)ACETAMIDA; (+/-)-[3-METIL-4-(6-METIL-PIRIDIN-3-ILOXI)-FENIL]-(6-PIPERIDIN-3-ILETINIL-QUINAZOLIN-4-IL)-AMINA; ENTRE OTROS; TAMBIEN SE REFIERE A COMPUESTOS DE FORMULA M-C=C-(CR16R17)t-R9; M ES H, B(R19)2, Al(R20)2, Sn(R21)3, MgW, ZnW; R19 ES ALQUILO, ALCOXI, CICLOALQUILO, ENTRE OTROS. LOS COMPUESTOS I PUEDEN SER UTILES PARA EL TRATAMIENTO DEL CRECIMIENTO ANORMAL COMO CANCER
PE2002001129A 2001-11-30 2002-11-25 Procedimientos para la preparacion de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal PE20030643A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33464701P 2001-11-30 2001-11-30

Publications (1)

Publication Number Publication Date
PE20030643A1 true PE20030643A1 (es) 2003-07-23

Family

ID=23308141

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001129A PE20030643A1 (es) 2001-11-30 2002-11-25 Procedimientos para la preparacion de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal

Country Status (28)

Country Link
US (1) US20030144506A1 (es)
EP (1) EP1448551B1 (es)
JP (1) JP4220388B2 (es)
KR (1) KR20040054813A (es)
CN (1) CN1639149A (es)
AR (1) AR037591A1 (es)
AT (1) ATE377009T1 (es)
AU (1) AU2002337428A1 (es)
BR (1) BR0214606A (es)
CA (1) CA2462149C (es)
DE (1) DE60223279T2 (es)
DO (1) DOP2002000519A (es)
ES (1) ES2295409T3 (es)
GT (1) GT200200245A (es)
HN (1) HN2002000334A (es)
HU (1) HUP0500117A3 (es)
IL (1) IL160971A0 (es)
MX (1) MXPA04005157A (es)
PA (1) PA8558601A1 (es)
PE (1) PE20030643A1 (es)
PL (1) PL370911A1 (es)
RS (1) RS44004A (es)
RU (1) RU2004116345A (es)
SV (1) SV2004001419A (es)
TN (1) TNSN02096A1 (es)
TW (1) TW200300691A (es)
WO (1) WO2003045939A1 (es)
ZA (1) ZA200402054B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054585A1 (en) * 2002-12-18 2004-07-01 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth
BR0317259A (pt) * 2002-12-19 2005-11-08 Pfizer Prod Inc Complexos de e-2-metóxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-ilóxi)-fenil amino]- quinazolin-6-il}-alil)-acetamida, seus métodos de produção e utilização
WO2004089934A1 (en) * 2003-04-09 2004-10-21 Pfizer Products Inc. Processes for the preparation of n-((((pyridinyloxy) -phenylamino) quinazolinyl)- allyl) acetamide derivatives and related compounds as well as intermediates of such processes and processes for the preparation of such intermediates
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2005003100A2 (en) * 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
ME01267B (me) 2004-05-06 2013-06-20 Warner Lambert Co 4-fenilaminokinazolin-6-ilamidi
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
KR20080082667A (ko) * 2005-12-02 2008-09-11 더 페이퍼 프로덕츠 리미티드 포장용 홀로그래픽 플렉시블 튜브 라미네이트 및 이의 제조방법
BR112021005513A2 (pt) 2018-09-25 2021-06-22 Black Diamond Therapeutics, Inc. derivados de quinazolina como inibidor de tirosina quinase, composições, métodos de fabricação e uso dos mesmos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW321649B (es) * 1994-11-12 1997-12-01 Zeneca Ltd
DE19501481A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 2,8-Disubstituierte Chinazolinone
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
MXPA02012870A (es) * 2000-06-22 2003-05-14 Pfizer Prod Inc Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.

Also Published As

Publication number Publication date
ATE377009T1 (de) 2007-11-15
AR037591A1 (es) 2004-11-17
AU2002337428A1 (en) 2003-06-10
TNSN02096A1 (en) 2005-12-23
DE60223279D1 (de) 2007-12-13
HUP0500117A3 (en) 2008-03-28
US20030144506A1 (en) 2003-07-31
HUP0500117A2 (hu) 2005-05-30
PA8558601A1 (es) 2003-06-30
CA2462149C (en) 2010-06-22
CN1639149A (zh) 2005-07-13
JP2005515986A (ja) 2005-06-02
CA2462149A1 (en) 2003-06-05
IL160971A0 (en) 2004-08-31
RS44004A (en) 2006-10-27
DOP2002000519A (es) 2003-05-31
KR20040054813A (ko) 2004-06-25
MXPA04005157A (es) 2004-08-11
DE60223279T2 (de) 2008-05-29
JP4220388B2 (ja) 2009-02-04
RU2004116345A (ru) 2005-03-27
SV2004001419A (es) 2004-02-24
BR0214606A (pt) 2004-09-14
PL370911A1 (en) 2005-05-30
EP1448551A1 (en) 2004-08-25
GT200200245A (es) 2003-09-24
WO2003045939A1 (en) 2003-06-05
TW200300691A (en) 2003-06-16
ES2295409T3 (es) 2008-04-16
EP1448551B1 (en) 2007-10-31
HN2002000334A (es) 2003-02-21
ZA200402054B (en) 2005-05-23

Similar Documents

Publication Publication Date Title
PE20030643A1 (es) Procedimientos para la preparacion de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal
AR013184A1 (es) Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
PE20211700A1 (es) Compuesto heterociclico y su uso
PE20020593A1 (es) Activadores de glucocinasa del tipo isoindolin-2-ona
PE20070519A1 (es) Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c
PE20090069A1 (es) Agonistas de adrenorecptores alfa2c funcionalmente selectivos
CO4440628A1 (es) Derivados de pirimidina condensados con un anillo heteroci- clico
BRPI0412999A (pt) 2-aminotetralina substituìda para tratamento de depressão
PE20030944A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
PE20040828A1 (es) Benzoxazinonas como modulares de 5-hidroxitriptamina (5-ht)
PE20040267A1 (es) Tiopirimidinas e isotiazolpirimidinas inhibidoras de quinasas
PA8475401A1 (es) Compuestos de sulfonilbenceno como agentes antiinflamatorios/analgesicos
TR200201783T2 (tr) 5-Siyanofatalid hazırlamak için yöntem
TW200609228A (en) Substituted n-acyl-2-aminothiazoles
LV11323A (lv) Izohinolina atvasinajumi ka arstnieciskie lidzekli
IL113414A0 (en) Methyl alpha -phenylbutenoates their preparation and use
AR025380A1 (es) Las rutas sinteticas eficientes para la preparacion de los inhibidores de la proteasa del rinovirus.
DE69517371D1 (de) 4-p-fluorbenzoyl-1-piperidinyl-propoxy-chromen-4-on derivate, deren herstellung und deren verwendung zur behandlung von psychosen und schizophrenie
RS4904A (en) Pharmaceutical composition for the treatment of the decline and/or damage of cognitive functions
PE20020339A1 (es) Derivados de pirrolidin como inhibidores de las metaloproteasas
ES2161892T3 (es) Derivados de indol como profarmacos de agonistas de los receptores afines a 5-ht1.
ES493926A0 (es) Procedimiento para la preparacion de nuevos derivados de 3-amino-1-benzoxepina
ATE53385T1 (de) Sulfinyl- und sulfonylsubstituierte 3benzazepine.
NZ594754A (en) Biologically active compounds derived from Centipeda cunninghamii

Legal Events

Date Code Title Description
FC Refusal